Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept Talidomida, peginterferón alfa-2b y ribavirina en el tratamiento de pacientes no respondedores con hepatitis crónica C genotipo 1: estudio piloto

Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept Talidomida, peginterferón alfa-2b y ribavirina en el tratamiento de pacientes no respondedores con hepatitis crónica C genotipo 1: estudio piloto

Background: fewer than half of patients infected with hepatitis C virus (HCV) achieve sustained viral clearance after peginterferon alfa/ribavirin (Peg-IFN/RBV) therapy. Aims: thalidomide posses anti-inflammatory and immunomodulatory properties through inhibition of tumor necrosis factor and costimu...

Full description

Bibliographic Details
Main Authors: Benjamín Pardo-Yules, Rocío Gallego-Durán, Mohammed Eslam, Carlos García-Collado, Lourdes Grande, Carmen Paradas, Ramón Morillo, Benito Dorantes, Manuel Romero-Gómez
Format: Article
Language:English
Published: Aran Ediciones 2011-12-01
Series:Revista Espanola de Enfermedades Digestivas
Subjects:
Hepatitis C
Factores del huésped
Talidomia
Factor de necrosis tumoral
Gammaglutamil transpeptidasa
Host factors
Thalidomide
TNF-&alpha
Clinical trial
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082011001200003

Similar Items

Similar Items